Checkpoint Therapeutics Inc

NASDAQ:CKPT   11:27:30 AM EDT
1.10
-0.02 (-2.23%)
Regulatory, Earnings Announcements

Checkpoint Therapeutics Announces Positive Interim Results From Registration-Enabling Trial Of Cosibelimab In Locally Advanced Cutaneous Squamous Cell Carcinoma

Published: 06/16/2022 11:41 GMT
Checkpoint Therapeutics Inc (CKPT) - Checkpoint Therapeutics Announces Positive Interim Results From Registration-enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma.
Checkpoint Therapeutics Inc - Objective Response Rate of 54.8% in Patients With Locally Advanced Cscc, a Potential 2(nd) Indication for Cosibelimab.
Checkpoint Therapeutics Inc - Previously Met Primary Endpoint in Patients With Metastatic Cscc; Bla Submission on Track for Later This Year.
Checkpoint Therapeutics Inc - to Continue Discussions With FDA on Potential Addition of Locally Advanced Indication to Its Planned Bla Submission.
Revenue is expected to be $0.02 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $0.02 Million
Next Quarter EPS Guidance is expected to be -$0.16

More details on our Analysts Page.